menu
    • menu
    [{"orgOrder":0,"company":"Auro Pharma Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Pazopanib Hydrochloride","moa":"Fibroblast growth factor receptor 1 | Tyrosine-protein kinase LCK | Stem cell growth factor receptor | Platelet-derived growth factor receptor | Fibroblast growth factor receptor 3 | Macrophage colony stimulating factor receptor | Vascular endothelial growth factor receptor | Tyrosine-protein kinase ITK\/TSK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Auro Pharma Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Auro Pharma Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Auro Pharma Inc \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Auro Pharma Inc

    Menu

    Auro Pharma Inc

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Auro Pharma Inc

                            Canada arrow
                            BioFit
                            Not Confirmed

                            Auro Pharma Inc

                            Canada arrow
                            BioFit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pazopanib Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Auro Pharma Arm Gets USFDA Nod for Pazopanib Tablet

                            Details : Vorient-Generic (pazopanib) is a kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma & advanced soft tissue sarcoma who have received prior chemotherapy.

                            Product Name : Vorient-Generic

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 05, 2024

                            Lead Product(s) : Pazopanib Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth